Receptor Activator of Nuclear Factor κ B Ligand (RANKL)

RANKL is a homotrimeric protein that exists as either a membrane-bound form on osteoblastic and activated T cells or as a secreted protein[2][3]. The secreted form is derived from the membrane form through proteolytic cleavage by matrix metalloproteases (MMP3 or MMP7) or ADAM (a disintegrin and metalloprotease domain)[2].\n\nRANKL functions by binding to its receptor RANK, which is expressed on progenitor and mature osteoclasts, activated T cells, and myeloid-derived dendritic cells[3]. This binding induces osteoclast differentiation, activation, and survival, leading to enhanced bone resorption and potential bone loss[3][5]. The interaction between RANKL and RANK forms a heterohexameric complex, with only two of the four RANK cysteine-rich domains (CRDs) in direct contact with RANKL[4][5].\n\nThe RANKL-RANK signaling pathway is tightly regulated by osteoprotegerin (OPG), which acts as a decoy receptor that prevents RANKL from interacting with RANK[3]. This molecular triad (RANKL/RANK/OPG) is crucial for maintaining bone homeostasis, and imbalances can lead to various pathological conditions[1][5].\n\nUpon binding to RANK, RANKL activates intracellular signaling cascades involving c-Jun, NF-κB, and serine/threonine kinase Akt/PKB pathways[3]. The cytoplasmic domain of RANK binds to TNF receptor-associated factors (TRAFs) 1, 2, 3, 5, and 6, which transmit signals to downstream targets[4].\n\nRANKL is highly expressed in lymph nodes, thymus, mammary glands, and lung, with lower expression in spleen and bone marrow[2]. Most factors that stimulate osteoclast formation and activity induce RANKL expression by osteoblastic stromal cells[2].\n\nThe high-affinity interaction between RANKL and RANK (with a dissociation constant up to 10^-11 M) is maintained by continuous contact rather than patched interaction, which is necessary for proper function, as even slight disruption of this binding can significantly impair osteoclast formation[5].

Other names

TRANCETNFSF11Osteoprotegerin ligand

Inhibition of RANKL binding to RANK receptor\nPrevention of osteoclast formation and activation\nReduction of bone resorption